Tyrosine kinase inhibitors
|PHA conventional pharmacology|
mixed retargeted oncopharmaceuticals
|32408336 2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets|
BTK Bruton Tyrosine Kinase ibrutiib
32302379 2020. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients
32503877 2020. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.
32433778 2020. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
|32552307 2020. A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors.|
32519895 2020. Is targeting Akt a viable option to treat advanced-stage COVID-19 patients?
Abelson tyrosine kinase
32399097 2020. Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2.
32395220 2020. SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection.
32422320 2020. p38 MAPK inhibition: A promising therapeutic approach for COVID-19.